Thermo Fisher Scientific has enrolled the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry, marking a major step toward building regulatory-grade real-world evidence in Alzheimer’s care.
Why This Registry Matters?
Alzheimer’s disease remains one of the most complex and costly neurological disorders worldwide. Despite recent therapeutic advances, long-term safety and real-world effectiveness data are still limited.
This new registry aims to close that gap.
What the PPD CorEvitas Alzheimer’s Registry Will Do?
The registry is designed as a global, multi-country initiative operating under a common protocol. Its focus is simple: capture how Alzheimer’s therapies perform in real clinical practice.
Key objectives include:
- Tracking long-term drug safety and effectiveness
- Understanding real-world treatment patterns
- Evaluating outcomes linked to approved therapies
- Identifying unmet medical needs across disease stages
The registry uses longitudinal, clinician-reported data, collected during routine care, to reflect how treatments work outside controlled clinical trials.
Safety Monitoring at the Core
A major strength of the registry is its detailed safety assessment framework.
This includes:
- MRI-based monitoring of brain swelling and bleeding
- Evaluation of plaque clearance as a treatment effectiveness marker
- Correlation of biological outcomes with cognitive changes
Together, these data points will help regulators and clinicians better balance benefit versus risk.
Addressing a Growing Public Health Challenge
Alzheimer’s disease affects an estimated 7.2 million Americans aged 65 and older, a number expected to double by 2050.
It is already a leading cause of death in the US. Yet, there is no cure—only therapies that may manage symptoms or slow progression. That makes high-quality real-world evidence essential.
Building Regulatory-Grade Evidence
According to Thermo Fisher, the registry is designed to meet regulatory expectations worldwide.
“We are building a regulatory-grade, real-world evidence foundation that will help shape the understanding of current and next-generation therapies,” said Peter Wahl, Vice President and Global Head of Scientific Affairs, PPD CorEvitas Clinical Registries.
Part of a Larger Registry Ecosystem
The Alzheimer’s registry expands Thermo Fisher’s PPD CorEvitas portfolio, which already includes:
- Over 500 investigator sites globally
- Longitudinal data from more than 100,000 patients
- Proven use in post-authorization safety studies
These registries are already recognized by global regulators.
The Bigger Picture
As Alzheimer’s drug development accelerates, real-world data will increasingly guide:
- Regulatory decisions
- Clinical practice
- Patient and caregiver expectations
With this registry, Thermo Fisher is positioning itself at the center of that evidence ecosystem.
